Value through Innovation05 September 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Boehringer Ingelheim licenses Vectron Biosolutions’ expression technology platform


ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim


Expansion of the Boehringer Ingelheim Board of Managing Directors / Andreas Neumann responsible for Human Resources


FDA and EMA accept regulatory applications for Boehringer Ingelheim’s Giotrif® / Gilotrif® (afatinib) for treatment of advanced squamous cell carcinoma of the lung


Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events


CHMP recommends label update for Giotrif® with addition of data demonstrating overall survival benefit for patients with EGFR mutation-positive lung cancer


New data show Spiolto® Respimat® provides meaningful quality of life improvements in COPD


Boehringer Ingelheim and Circuit Therapeutics announce new collaboration to discover novel medicines for obesity


Boehringer Ingelheim experiences slight growth in local currency terms in the first half of 2015


Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer


MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke


Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)


Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) in patients with previously treated advanced squamous cell carcinoma of the lung


New advance in COPD maintenance treatment, Spiolto® Respimat®, approved in first European countries


Boehringer Ingelheim Animal Health: 2015 European PRRS Research Award open for submissions until July 31st


Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study


New publication in The Lancet describes effective reversal of Pradaxa® in healthy volunteers


Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16